

Project Title: Decreasing Chemotherapy Administration Delays in Electively Admitted patients to a Hematology-Oncology Unit

Presenter's Name: Adolfo Enrique Diaz, MD, MSc


Institution: UT Health San Antonio / Mays Cancer Center

Date: 06/18/21



Institutional Overview





We are 69% Hispanic:

- 4.9 M people (31% NHW, 4% AA)
- Catchment Area: 38 Counties
- 4200 new oncology cases per year
- NCI Cancer Designated Center
- Unique population characteristics:
 - Age (40% < 25 years of age)
 - Language (41% speak Spanish as primary language)
 - Income (24% in poverty; \$30,135 per capita personal income)
 - Education (26% No HS education)
 - Military veterans (9%)





Team members



Mary Salazar, DNP, MSN, RN
Director of Oncology Patient Experience
Team Member



Geary Delgado, MSN, RN
Patient Care Coordinator UHS
Team Member



Jeremy Viles, DNP, MBA, RN Chief Nursing Officer Team Member



Enrique Diaz, MD, MSc

Assistant Professor of Medicine Hematology-Oncology Team Leader



Nikos Papanikolaou, PhD Professor Radiation Oncology. Chair Radiation Physics Team Member



Valorie Harvey, BSN, MBA

QTP Coach



Problem Statement



An average of 20-25 patients were electively admitted to UHS per month in 2019 for inpatient chemotherapy administration. The median time between the patient is admitted to UHS and chemotherapy is started is 19.1 hours. This delay results in an increased LOS and resource utilization along with decreased patient satisfaction.





Outcome Measure Baseline data summary



Item	Description
Measure:	Time from admission to UHS to time of chemotherapy initiation.
Patient population: (Exclusions, if any)	Patients seen at MCC and electively admitted to UHS for chemotherapy. 18 y.o and older
Calculation methodology: (i.e. numerator & denominator)	(Time of administration of chemo – Time of arrival to hospital) on each elective admit / # of patients
Data source:	EMR
Data collection frequency:	March of 2019 / Pre COVID-19 era / Weekly
Data limitations: (if applicable)	Limited sample Manual abstraction








Baseline Data March 2019 X Chart

Minimum 3.28h

Maximum 110h

• Median 19.4h







Aim Statement



AIM STATEMENT

A decrease by 10% in the current 19.4 hours as median time of chemotherapy start is projected by June 1st 2021

Process map








Priority / Pay-off Matrix Countermeasures





Ease of Implementation






Cause and Effect diagram




Human Factor





Process Measure Diagnostic Data







Process Measure Diagnostic data summary



Item	Description
Measure:	Time from admission to UHS to time of chemotherapy initiation.
Patient population: (Exclusions, if any)	Patients seen at MCC and electively admitted to UHS for chemotherapy. 18 y.o and older
Calculation methodology: (i.e. numerator & denominator)	(Time of administration of chemo – Time of arrival to hospital) on each elective admit / # of patients
Data source:	EMR
Data collection frequency:	2021 data on monthly basis
Data limitations: (if applicable)	Manual abstraction Limited sample





Test of Change PDSA Plan



Date	PDSA Cycle	PDSA Description
03/12/21 – 03/31/21	1	Reserve beds for elective admits on Mondays and Tuesdays
04/01/21 – 04/30/21	2	 "OK" note from inpatient to give chemotherapy Distribute patients uniformly throughout all working days of the week








Change Data PDSA 1 / March 2021 X Chart

- Minimum 3.3h
- Maximum 40. 2h

Median 8.5h










Outcome Measure

Baseline / X Chart

PDSA 1 / X Chart










Change Data PDSA 2 / April 2021 X Chart

Minimum 1.52h

• Maximum 71 h

• Median 7.03h










Outcome Measure


PDSA 1 / X Chart

PDSA 2 / X Chart









- - - LCL



→ Maximun Baseline → Median Baseline --- UCL



Test of Change PDSA Plan



1 Reserve beds for elective admits on Mondays and Tuesdays 04/01/21 2 • "OK" note from inpatient to give chemotherapy • Distribute patients homogeneously throughout all working days of the week Improvement Adopt Adopt Improvement Adopt Improvement Adopt Improvement Adopt Adopt Improvement Adopt Improvement Adopt Adopt Improvement Improvement Improvement Improvement Improvement Improvement Imp	Date	PDSA Cycle	PDSA Description	Result	Action Step
- inpatient to give chemotherapy • Distribute patients homogeneously throughout all working days of the	_	1	elective admits on	Improvement	Adopt
	_	2	 inpatient to give chemotherapy Distribute patients homogeneously throughout all working days of the 		Adopt





Next steps **Sustainability Plan**

Next Steps	Owner
Continue to work with UHS leadership to get the ability to reserve beds for all working days.	Enrique Diaz / Kate Lathrop
Approach pharmacy leadership to work on more flexible / late cut-off time for chemotherapy mix.	Enrique Diaz / Gary Hill



Conclusions

- Over a 3-month period, we achieved our goal by reducing the median time from patient arrival to initiating chemotherapy from 19.4 hours to 7.3 hours.
- The biggest impact was achieved by the ability to reserve beds for elective admissions.
- Meaningful improvements in chemotherapy delays can only be achieved by the coordinated work of a multidisciplinary team and investment of key stakeholders.

